You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
23 October 2026 - RNAi (RNA interference) therapeutics company Alnylam Pharmaceuticals Inc (Nasdaq:ALNY) on Friday reported positive initial Phase 1b clinical trial results for brezosiran, an investigational RNAi therapy for Huntington's disease...
23 October 2026 - Zai Lab Limited (NASDAQ:ZLAB) (HKEX:9688), a research-based, commercial-stage biopharmaceutical company based in China and the United States, on Friday reported promising initial results from a global Phase 1b trial evaluating zocil...
23 October 2026 - Biopharmaceutical company HUYABIO International announced on Thursday that oral HBI-8000 in combination with intravenous nivolumab reduced the risk of disease progression or death by 27% compared with nivolumab alone in a global Pha...
23 October 2026 - South Korea-based ImmunoForge Co Ltd, a clinical-stage biopharmaceutical company focused on developing therapies for rare, neuromuscular, metabolic diseases, and targeted oncology, announced on Thursday that its executive management...
22 October 2026 - The Institute for Healthcare Improvement (IHI) and biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) on Thursday launched a three-year Cancer Collective Action Collaborative to expand access to and participation in oncology ...
21 October 2026 - Swiss pharmaceutical company Novartis AG (SIX: NOVN; NYSE: NVS) on Wednesday said the European Commission has approved Cosentyx (secukinumab) for adults with polymyalgia rheumatica (PMR) who have had an inadequate response to glucoc...
21 October 2026 - Edwards Lifesciences Corporation (NYSE: EW), a structural heart innovation company, announced on Wednesday that it has received US Food and Drug Administration (FDA) approval for its PASCAL Precision system to repair the tricuspid v...